Literature DB >> 36262740

Common Co-Morbidities in Heart Failure - Diabetes, Functional Mitral Regurgitation and Sleep Apnoea.

Andrew J Stewart Coats1.   

Abstract

Heart failure (HF) is a condition that carries a considerable burden of disability many now related to co-existing co-morbidities. The drive to find newer effective therapies targeting novel mechanisms has led to a recent emphasis on treating common co-morbidities that are clustered around contemporary HF patients. Here is renewed contemporary co-morbidities that until recently have received little attention but which are now subject of considerable interest and potential therapeutic advance. These include, diabetes, functional mitral regurgitation and sleep disordered breathing. These three contemporary co-morbidities that have recently been subject to major trial evaluation will be reviewed in this paper.
Copyright © 2019. Korean Society of Heart Failure.

Entities:  

Keywords:  Comorbidity; Diabetes mellitus; Heart failure; Mitral regurgitation; Sleep-disordered breathing

Year:  2019        PMID: 36262740      PMCID: PMC9536668          DOI: 10.36628/ijhf.2019.0004

Source DB:  PubMed          Journal:  Int J Heart Fail        ISSN: 2636-154X


  75 in total

1.  Prevalence and severity of mitral regurgitation in chronic systolic heart failure.

Authors:  Joel D Robbins; Parimal B Maniar; William Cotts; Michele A Parker; Robert O Bonow; Mihai Gheorghiade
Journal:  Am J Cardiol       Date:  2003-02-01       Impact factor: 2.778

2.  Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study.

Authors:  Joanna L d'Arcy; Sean Coffey; Margaret A Loudon; Andrew Kennedy; Jonathan Pearson-Stuttard; Jacqueline Birks; Eleni Frangou; Andrew J Farmer; David Mant; Jo Wilson; Saul G Myerson; Bernard D Prendergast
Journal:  Eur Heart J       Date:  2016-06-26       Impact factor: 29.983

Review 3.  Metabolic therapy for patients with diabetes mellitus and coronary artery disease.

Authors:  Giuseppe M C Rosano; Cristiana Vitale; Gabriele Fragasso
Journal:  Am J Cardiol       Date:  2006-07-24       Impact factor: 2.778

4.  Long-term effects of intensive glucose lowering on cardiovascular outcomes.

Authors:  Hertzel C Gerstein; Michael E Miller; Saul Genuth; Faramarz Ismail-Beigi; John B Buse; David C Goff; Jeffrey L Probstfield; William C Cushman; Henry N Ginsberg; J Thomas Bigger; Richard H Grimm; Robert P Byington; Yves D Rosenberg; William T Friedewald
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

5.  Continuous positive airway pressure for central sleep apnea and heart failure.

Authors:  T Douglas Bradley; Alexander G Logan; R John Kimoff; Frédéric Sériès; Debra Morrison; Kathleen Ferguson; Israel Belenkie; Michael Pfeifer; John Fleetham; Patrick Hanly; Mark Smilovitch; George Tomlinson; John S Floras
Journal:  N Engl J Med       Date:  2005-11-10       Impact factor: 91.245

6.  High prevalence of sleep apnea in heart failure outpatients: even in patients with preserved systolic function.

Authors:  Tobias E Herrscher; Harriet Akre; Britt Øverland; Leiv Sandvik; Arne S Westheim
Journal:  J Card Fail       Date:  2011-03-25       Impact factor: 5.712

7.  Pathogenesis of Cheyne-Stokes respiration in patients with congestive heart failure. Relationship to arterial PCO2.

Authors:  P Hanly; N Zuberi; R Gray
Journal:  Chest       Date:  1993-10       Impact factor: 9.410

8.  Role of hyperventilation in the pathogenesis of central sleep apneas in patients with congestive heart failure.

Authors:  M Naughton; D Benard; A Tam; R Rutherford; T D Bradley
Journal:  Am Rev Respir Dis       Date:  1993-08

9.  Increased mortality associated with Cheyne-Stokes respiration in patients with congestive heart failure.

Authors:  P J Hanly; N S Zuberi-Khokhar
Journal:  Am J Respir Crit Care Med       Date:  1996-01       Impact factor: 21.405

10.  Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Jennifer B Green; M Angelyn Bethel; Paul W Armstrong; John B Buse; Samuel S Engel; Jyotsna Garg; Robert Josse; Keith D Kaufman; Joerg Koglin; Scott Korn; John M Lachin; Darren K McGuire; Michael J Pencina; Eberhard Standl; Peter P Stein; Shailaja Suryawanshi; Frans Van de Werf; Eric D Peterson; Rury R Holman
Journal:  N Engl J Med       Date:  2015-06-08       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.